Important Information for Patients and Healthcare Professionals
Resmetirom is an oral selective thyroid hormone receptor-beta agonist used for a defined group of adults with metabolic dysfunction-associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH), and moderate to advanced liver fibrosis without cirrhosis.
Resiliva is identified on this website as a product containing resmetirom in stated strengths of 80 mg and 100 mg. The specific prescribing information, manufacturer and authorization status of Resiliva have not been independently confirmed.
The information below summarizes key considerations associated with the established reference product, REZDIFFRA. It is not a substitute for the full, current prescribing information applicable to the exact product and jurisdiction.
Approved Therapeutic Use
The U.S. Food and Drug Administration approved REZDIFFRA on March 14, 2024. Its U.S. indication is treatment, alongside diet and exercise, of adults with noncirrhotic MASH and moderate to advanced liver fibrosis consistent with stages F2 to F3.
The FDA approval was granted under the accelerated approval pathway based on improvement in MASH and fibrosis. Continued approval may depend on confirmation of clinical benefit in further studies. <Cite refs={[“turn249135search3″,”turn249135search8”]}/>
This indication should not be generalized to every patient with fatty liver disease, other liver conditions or cirrhosis. Eligibility must be determined by a qualified healthcare professional.
Dosage and Administration
Under the U.S. REZDIFFRA prescribing information, the recommended adult dose is based on actual body weight:
- Less than 100 kg: 80 mg orally once daily.
- 100 kg or more: 100 mg orally once daily.
The reference product can be taken with or without food. Other medicines, particularly certain CYP2C8 inhibitors and statins, can affect treatment recommendations. The full prescribing information should be consulted for the appropriate adjustments and restrictions. <Cite refs={[“turn249135search3″,”turn249135search22”]}/>
These instructions do not independently establish the authorized dose of Resiliva. Patients must follow the instructions for their prescribed product and should not adjust their dose without professional guidance.
Contraindications and Limitations of Use
The current reference-product prescribing information should be reviewed for contraindications and limitations relevant to the patient’s condition and concurrent medicines.
The U.S. reference product includes a limitation concerning decompensated cirrhosis. Patients with advanced liver disease should not assume that resmetirom is suitable for them without specialist assessment. <Cite refs={[“turn249135search2″,”turn249135search10”]}/>
The absence of a contraindication on this summary does not establish that treatment is appropriate for a particular patient.
Important Warnings
Liver injury
The U.S. reference-product labeling includes a warning concerning hepatotoxicity. Patients should be advised about symptoms that may suggest liver injury, including jaundice, dark urine or persistent unusual fatigue, and should promptly seek medical assessment if these occur.
Gallbladder-related adverse reactions
Gallstones and gallbladder inflammation are important safety considerations. New or severe abdominal pain should be evaluated rather than automatically attributed to a routine digestive side effect.
Drug interactions
Resmetirom interacts with certain medicines, including some statins and medicines that affect CYP2C8. Healthcare professionals should review the full medication list and use the applicable prescribing information to determine whether changes or additional monitoring are needed.
Adverse Reactions
Reported adverse reactions include diarrhea, nausea, itching, vomiting, constipation, abdominal discomfort and dizziness. The likelihood and severity of adverse reactions vary between patients.
Patients should report persistent or worsening symptoms to their healthcare professional. Serious symptoms require prompt assessment, and severe or rapidly worsening symptoms may require emergency care.
Clinical Monitoring
Monitoring should be individualized according to the patient’s condition and current prescribing information. The treating team may assess liver-related symptoms, relevant laboratory results, tolerability and potential medicine interactions.
Patients should attend scheduled appointments and should not discontinue monitoring because they feel well. Liver disease can progress without obvious symptoms.
Pregnancy and Breastfeeding
Pregnancy and breastfeeding considerations should be reviewed using the current product-specific prescribing information and the patient’s clinical circumstances. Patients who are pregnant, planning pregnancy or breastfeeding should discuss treatment with a qualified healthcare professional before making decisions.
Do not assume that the absence of detailed information in this summary means that a medicine is safe during pregnancy or breastfeeding.
Storage and Handling
Follow the storage conditions in the official package insert for the exact prescribed product. Do not assume that Resiliva has identical storage requirements to REZDIFFRA.
Keep medicine away from children and do not use a product that is expired or has damaged or suspicious packaging without obtaining professional advice.
Reporting Suspected Adverse Reactions
Patients should report suspected adverse reactions to their healthcare professional. Reporting through the relevant national pharmacovigilance system may also be appropriate.
For a suspected product-quality or authenticity concern, preserve the packaging and relevant batch information where possible and contact a pharmacist or the relevant regulatory authority.
Medical Disclaimer
This page is an educational summary, not a complete prescribing document. It does not replace the current official label or establish Resiliva’s authorization, formulation or interchangeability with REZDIFFRA.
Healthcare professionals and patients should consult the full prescribing information applicable to the exact product and jurisdiction before making treatment decisions.
References
- U.S. FDA and DailyMed: Current REZDIFFRA prescribing information.
- U.S. FDA: REZDIFFRA approval and clinical trial information.
- European Medicines Agency: REZDIFFRA product information.